Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 8/2002

01-08-2002 | Review Article

Outcomes of Lipid-Lowering Treatment in Postmenopausal Women

Author: Dr John C. LaRosa

Published in: Drugs & Aging | Issue 8/2002

Login to get access

Abstract

Elevated triglycerides and low high-density lipoprotein (HDL) levels are more important coronary risk factors in women, and elevated low-density lipoprotein (LDL) levels less important in women, than men. There is clear-cut evidence in clinical trials that the benefit of cholesterol lowering in women and men is virtually identical.
Modifiers of lipids and lipoproteins in women include diabetes mellitus, body-weight and its distribution, and menopausal status. Diabetes is a more powerful predictor of risk in women than men. This may relate to the importance of elevated triglycerides as a risk factor in women, and to the effects of lipoprotein glycosylation, which lead to increased susceptibility to arterial deposition of LDL and decreased reverse cholesterol transport with HDL.
Therapy for lipoprotein disorders in women and men is identical. For the overwhelming majority of patients, treatment with statin therapy is both highly efficacious and well tolerated.
Literature
1.
Bass KM, Newschaffer CJ, Klag MJ, et al. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993; 153: 2209–16PubMedCrossRef
2.
LaRosa JC. Triglycerides and coronary risk in women and the elderly. Arch Intern Med 1997; 157: 961–8PubMedCrossRef
3.
LaRosa JC. The pharmacology and effectiveness of specific lipid-active drugs: estrogen/sex steroids. Coron Artery Dis 1996; 7: 683–8PubMedCrossRef
4.
Kannel WB. Nutrition and the occurrence and prevention of cardiovascular disease in the elderly. Nutr Rev 1984; 46: 68–78CrossRef
5.
World Health Organization. Japan outscores USA in longevity ranking. USA Today 2000 June 5; Sect. D: 6
6.
Manolio TA, Pearson TA, Wenger NK, et al. Cholesterol and heart disease in older persons and women: review of an NHLBI workshop. Ann Epidemiol 1992; 2: 161–76PubMedCrossRef
7.
LaRosa JC. Cholesterol agonistics. Ann Intern Med 1996; 124: 505–8PubMed
8.
LaRosa JC, He J, Vupputuri S. Effects of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282: 2340–6PubMedCrossRef
9.
Sandkamp M, Assmann G. Lipoprotein(a) in PRO-CAM participants and young myocardial infarction survivors. In: Scanu AM, editor. Lipoprotein(a). New York (NY): Academic Press, 1990: 205–9
10.
Brewer HB. Effectiveness of diet and drugs in the treatment of patients with elevated Lp(a) levels. In: Scanu AM, editor. Lipoprotein(a). New York: Academic Press, 1990: 211–20
11.
Krolewski AS, Warram JH, Valsania P, et al. Evolving natural history of coronary artery disease in diabetes mellitus. Am J Med 1991; 90(2A): 56S–61SPubMedCrossRef
12.
Verges BL. Dyslipidaemia in diabetes mellitus: review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis. Diabetes Metab 1999; 25(S3): 32–40PubMed
13.
Soler JT, Folsom AR, Kushi LH, et al. Association of body fat distribution with plasma lipids, lipoproteins, apolipoproteins A-1 and B in postmenopausal women. J Clin Epidemiol 1988; 41: 1075–81PubMedCrossRef
14.
Lapidus L, Bengtsson C, Larsson B, et al. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. BMJ 1984; 289: 1257–61PubMedCrossRef
15.
Grodin JM, Siiteri PK, MacDonald PC. Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 1973; 36: 207–14PubMedCrossRef
16.
Barnard RJ. Effects of life-style modification on serum lipids. Arch Intern Med 1991; 151: 1389–94PubMedCrossRef
17.
Bush TL. The epidemiology of cardiovascular disease in postmenopausal women. Ann N Y Acad Sci 1990; 592: 263–71PubMedCrossRef
18.
van der Schouw YT, van der Graaf Y, Steyerberg EW, et al. Age at menopause as a risk factor for cardiovascular mortality. Lancet 1996; 347: 714–8PubMedCrossRef
19.
PEPI Investigators. Effects of estrogen or estrogen-progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273: 199–208CrossRef
20.
Adams MR, Register TC, Golden DL, et al. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 217–21PubMedCrossRef
21.
Psaty BM, Heckbert SR, Atkins D, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994; 154: 1333–9PubMedCrossRef
22.
Hulley S, Grady D, Bush T, et al., for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605–13PubMedCrossRef
23.
Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343: 522–9PubMedCrossRef
24.
Wood D, De Backer G, Faergeman O, et al., and Task Force Members. Prevention of coronary heart disease in clinical practice. Eur Heart J 1998; 19: 1434–503CrossRef
25.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–97CrossRef
26.
Robins SJ, Collins D, Wittes JT, et al., for the VA-HIT Study Group. Relation of gemfibrozil treatment and lipid levels with major coronary events. JAMA 2001; 285: 1585–91PubMedCrossRef
27.
BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102: 21–7CrossRef
28.
Mensink RP, Katan MB. Effect of monounsaturated fatty acids versus complex carbohydrates on high-density lipoproteins in healthy men and women. Lancet 1987; 8525: 122–5CrossRef
29.
Masarei JRL, Rouse IL, Lynch WJ, et al. Effects of a lacto-ovo vegetarian diet on serum concentration of cholesterol, triglyceride, HDL-C, HDL2-C, HDL3-C, apoprotein-B, and Lp(a). Am J Clin Nutr 1984; 40: 468–78PubMed
30.
Ernst N, Bowen P, Fisher M, et al. Changes in plasma lipids and lipoproteins after a modified fat diet. Lancet 1980; I: 111–3CrossRef
31.
Lokey EA, Tran ZV. Effects of exercise training on serum lipid and lipoprotein concentrations in women: a meta-analysis. Int J Sports Med 1989; 10: 424–9PubMedCrossRef
32.
Hartung GH, Moore CE, Mitchell R, et al. Relationship of menopausal status and exercise level to HDL cholesterol in women. Exp Aging Res 1984; 10: 13–8CrossRef
33.
Metadata
Title
Outcomes of Lipid-Lowering Treatment in Postmenopausal Women
Author
Dr John C. LaRosa
Publication date
01-08-2002
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 8/2002
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200219080-00005

Other articles of this Issue 8/2002

Drugs & Aging 8/2002 Go to the issue

Therapy In Practice

Acute Myeloid Leukaemia

Leading Article

Potential of Transdermal Drug Delivery in Parkinson’s Disease

Review Article

Strategies for Improving Quality of Life in Older Patients with Metastatic Breast Cancer

Leading Article

Gene Therapy for Renal Disorders

Therapy In Practice

Relapse Prevention and Maintaining Abstinence in Older Adults with Alcohol-Use Disorders
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits